In the latest trading session, Aytu Bioscience Inc (AYTU - Free Report) closed at $1.47, marking a +1.38% move from the previous day. This move outpaced the S&P 500's daily gain of 1.15%. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 1.42%.
Wall Street will be looking for positivity from AYTU as it approaches its next earnings report date. On that day, AYTU is projected to report earnings of -$0.39 per share, which would represent year-over-year growth of 22%. Our most recent consensus estimate is calling for quarterly revenue of $7 million, up 194.12% from the year-ago period.
AYTU's full-year Zacks Consensus Estimates are calling for earnings of -$1.26 per share and revenue of $22.12 million. These results would represent year-over-year changes of +63.79% and +202.14%, respectively.
Any recent changes to analyst estimates for AYTU should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AYTU currently has a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 11, putting it in the top 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Aytu Bioscience Inc (AYTU - Free Report) closed at $1.47, marking a +1.38% move from the previous day. This move outpaced the S&P 500's daily gain of 1.15%. Meanwhile, the Dow gained 0.89%, and the Nasdaq, a tech-heavy index, added 1.42%.
Wall Street will be looking for positivity from AYTU as it approaches its next earnings report date. On that day, AYTU is projected to report earnings of -$0.39 per share, which would represent year-over-year growth of 22%. Our most recent consensus estimate is calling for quarterly revenue of $7 million, up 194.12% from the year-ago period.
AYTU's full-year Zacks Consensus Estimates are calling for earnings of -$1.26 per share and revenue of $22.12 million. These results would represent year-over-year changes of +63.79% and +202.14%, respectively.
Any recent changes to analyst estimates for AYTU should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AYTU currently has a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 11, putting it in the top 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AYTU - FREE